BR0311548A - Tiofenos substituìdos, processo para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como medicamento contendo os mesmos - Google Patents
Tiofenos substituìdos, processo para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como medicamento contendo os mesmosInfo
- Publication number
- BR0311548A BR0311548A BR0311548-8A BR0311548A BR0311548A BR 0311548 A BR0311548 A BR 0311548A BR 0311548 A BR0311548 A BR 0311548A BR 0311548 A BR0311548 A BR 0311548A
- Authority
- BR
- Brazil
- Prior art keywords
- well
- medicine
- treatment
- diseases
- preparation
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229930192474 thiophene Natural products 0.000 title abstract 2
- 150000003577 thiophenes Chemical class 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 238000011282 treatment Methods 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940126601 medicinal product Drugs 0.000 abstract 2
- 208000030090 Acute Disease Diseases 0.000 abstract 1
- 208000017667 Chronic Disease Diseases 0.000 abstract 1
- 206010041235 Snoring Diseases 0.000 abstract 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10224892A DE10224892A1 (de) | 2002-06-04 | 2002-06-04 | Substituierte Thiophene, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| PCT/EP2003/005465 WO2003101984A1 (de) | 2002-06-04 | 2003-05-26 | Substituierte thiophene, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0311548A true BR0311548A (pt) | 2005-04-12 |
Family
ID=29557542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0311548-8A BR0311548A (pt) | 2002-06-04 | 2003-05-26 | Tiofenos substituìdos, processo para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como medicamento contendo os mesmos |
Country Status (32)
| Country | Link |
|---|---|
| EP (1) | EP1513834B1 (https=) |
| JP (1) | JP4511924B2 (https=) |
| KR (1) | KR101087966B1 (https=) |
| CN (1) | CN1324024C (https=) |
| AR (1) | AR040239A1 (https=) |
| AT (1) | ATE320425T1 (https=) |
| AU (1) | AU2003273553B2 (https=) |
| BR (1) | BR0311548A (https=) |
| CA (1) | CA2488242C (https=) |
| CR (1) | CR7577A (https=) |
| DE (2) | DE10224892A1 (https=) |
| DK (1) | DK1513834T3 (https=) |
| EC (1) | ECSP045471A (https=) |
| ES (1) | ES2258722T3 (https=) |
| HR (1) | HRP20041153A2 (https=) |
| IL (1) | IL165519A (https=) |
| MA (1) | MA27204A1 (https=) |
| ME (1) | MEP27608A (https=) |
| MX (1) | MXPA04011986A (https=) |
| MY (1) | MY129832A (https=) |
| NO (1) | NO329351B1 (https=) |
| OA (1) | OA12827A (https=) |
| PE (1) | PE20040534A1 (https=) |
| PL (1) | PL372589A1 (https=) |
| PT (1) | PT1513834E (https=) |
| RS (1) | RS51141B (https=) |
| RU (1) | RU2315766C2 (https=) |
| TN (1) | TNSN04240A1 (https=) |
| TW (1) | TWI283675B (https=) |
| UA (1) | UA77551C2 (https=) |
| WO (1) | WO2003101984A1 (https=) |
| ZA (1) | ZA200409095B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040242560A1 (en) | 2003-05-22 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Process for synthesizing heterocyclic compounds |
| DE10323701A1 (de) | 2003-05-22 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Verfahren zur Synthese heterocyclischer Verbindungen |
| JP4384635B2 (ja) | 2003-06-30 | 2009-12-16 | 住友化学株式会社 | 不斉尿素化合物およびこれを触媒として用いる不斉共役付加反応による不斉化合物の製造方法 |
| US20100056515A1 (en) * | 2006-10-25 | 2010-03-04 | Kazuyoshi Aso | Benzimidazole compounds |
| BRPI0918502A2 (pt) | 2008-09-02 | 2015-12-01 | Sanofi Aventis | aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos |
| RU2373929C1 (ru) * | 2008-11-11 | 2009-11-27 | Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) | Корректор системы гемостаза, проявляющий ингибирующее действие на адгезивно-агрегационную функцию тромбоцитов для профилактики патологического тромбообразования |
| CA2780031A1 (en) * | 2009-11-12 | 2011-05-19 | Selvita S.A. | A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
| RU2518740C1 (ru) * | 2013-03-22 | 2014-06-10 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" | СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ДИГИДРОХЛОРИД 2-(3,4-МЕТИЛЕНДИОКСИФЕНИЛ)-9-МОРФОЛИНОЭТИЛИМИДАЗО[1,2-a]БЕНЗИМИДАЗОЛА |
| ME03311B (me) | 2014-07-25 | 2019-10-20 | Taisho Pharmaceutical Co Ltd | Fenil teтrahidroizokvinolinsko jedinjenje supsтituisano heteroarilom |
| KR102840252B1 (ko) * | 2023-04-27 | 2025-07-30 | 한국화학연구원 | 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| CN120112529B (zh) * | 2023-09-28 | 2026-01-06 | 四川大学华西医院 | 一种含吡啶的化合物及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE754935A (fr) | 1969-08-13 | 1971-02-17 | Hoechst Ag | 2-(thienyl-3'-amino)-1,3-diazacycloalcenes et leur preparation |
| BR6915362D0 (pt) * | 1969-08-16 | 1973-01-04 | Hoechst Ag | Processo para a preparacao de 2(tienil-3-amino)1,3-diazacicloalquenos |
| DE2830279A1 (de) * | 1978-07-10 | 1980-01-31 | Boehringer Sohn Ingelheim | 2-eckige klammer auf n-(2'-chlor-4'- methyl-thienyl-3')-n-(cyclopropylmethyl)- amino eckige klammer zu-imidazolin-(2), dessen saeureadditionssalze, dieses enthaltende arzneimittel und verfahren zu seiner herstellung |
| US5395847A (en) * | 1993-12-02 | 1995-03-07 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids |
| AU747784B2 (en) * | 1998-07-29 | 2002-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
| DE19921883A1 (de) * | 1999-05-12 | 2000-11-16 | Bayer Ag | Substituierte Thienocycloalk(en)ylamino-1,3,5-triazine |
| DE19960204A1 (de) * | 1999-12-14 | 2001-06-28 | Aventis Pharma Gmbh | Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| NZ535985A (en) * | 2002-03-29 | 2007-04-27 | Chiron Corp | Substituted benzazoles and use thereof as RAF kinase inhibitors |
-
2002
- 2002-06-04 DE DE10224892A patent/DE10224892A1/de not_active Withdrawn
-
2003
- 2003-05-26 OA OA1200400321A patent/OA12827A/en unknown
- 2003-05-26 BR BR0311548-8A patent/BR0311548A/pt not_active IP Right Cessation
- 2003-05-26 PT PT03740148T patent/PT1513834E/pt unknown
- 2003-05-26 KR KR1020047019725A patent/KR101087966B1/ko not_active Expired - Fee Related
- 2003-05-26 CN CNB038128462A patent/CN1324024C/zh not_active Expired - Fee Related
- 2003-05-26 HR HR20041153A patent/HRP20041153A2/xx not_active Application Discontinuation
- 2003-05-26 AU AU2003273553A patent/AU2003273553B2/en not_active Ceased
- 2003-05-26 RS YUP-1038/04A patent/RS51141B/sr unknown
- 2003-05-26 MX MXPA04011986A patent/MXPA04011986A/es active IP Right Grant
- 2003-05-26 CA CA2488242A patent/CA2488242C/en not_active Expired - Fee Related
- 2003-05-26 WO PCT/EP2003/005465 patent/WO2003101984A1/de not_active Ceased
- 2003-05-26 PL PL03372589A patent/PL372589A1/xx not_active Application Discontinuation
- 2003-05-26 JP JP2004509675A patent/JP4511924B2/ja not_active Expired - Fee Related
- 2003-05-26 EP EP03740148A patent/EP1513834B1/de not_active Expired - Lifetime
- 2003-05-26 DK DK03740148T patent/DK1513834T3/da active
- 2003-05-26 DE DE50302673T patent/DE50302673D1/de not_active Expired - Lifetime
- 2003-05-26 ME MEP-276/08A patent/MEP27608A/xx unknown
- 2003-05-26 UA UA20041211000A patent/UA77551C2/uk unknown
- 2003-05-26 ES ES03740148T patent/ES2258722T3/es not_active Expired - Lifetime
- 2003-05-26 AT AT03740148T patent/ATE320425T1/de active
- 2003-05-26 RU RU2004138812/04A patent/RU2315766C2/ru not_active IP Right Cessation
- 2003-05-30 PE PE2003000531A patent/PE20040534A1/es not_active Application Discontinuation
- 2003-06-02 AR ARP030101958A patent/AR040239A1/es active IP Right Grant
- 2003-06-02 TW TW092114860A patent/TWI283675B/zh not_active IP Right Cessation
- 2003-06-03 MY MYPI20032052A patent/MY129832A/en unknown
-
2004
- 2004-11-10 ZA ZA200409095A patent/ZA200409095B/xx unknown
- 2004-11-16 MA MA27952A patent/MA27204A1/fr unknown
- 2004-11-19 CR CR7577A patent/CR7577A/es unknown
- 2004-12-02 IL IL165519A patent/IL165519A/en not_active IP Right Cessation
- 2004-12-02 EC EC2004005471A patent/ECSP045471A/es unknown
- 2004-12-03 TN TNP2004000240A patent/TNSN04240A1/en unknown
- 2004-12-16 NO NO20045504A patent/NO329351B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0309167A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação | |
| BR0307291A (pt) | Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; método para o tratamento e profilaxia de distúrbios diversos e de obesidade em um humano | |
| BR9910801A (pt) | Derivados da pirazolina, a preparação dos mesmose a aplicação dos mesmos como um medicamento | |
| BR0210838A (pt) | Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com glicogênio sintase quinase-3, e de doenças, e medicação contraceptiva, e, processos para a preparação de um composto | |
| BRPI0606930A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, métodos para a produção de um efeito de inibição de b-raf em um animal de sangue quente, para a produção de um efeito anti-cáncer em um animal de sangue quente e para o tratamento de doenças de um animal em um animal de sangue quente | |
| BR0210008A (pt) | Derivados de feniluréia substituìdos com carboxamida, processos para produção dos mesmos como medicamentos | |
| BRPI0512796A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf, e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença | |
| BR0315720A (pt) | Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário | |
| BR0212008A (pt) | Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste | |
| BR112012024379A2 (pt) | "peptídeos glucagon, seu uso, bem como composição farmacêutica" | |
| BRPI0507309A (pt) | derivados de ácido 7-fenilamino-4quinolon-3-carboxìlico, processos para produção e seu uso como medicamento | |
| BR0014525A (pt) | Processo de tratamento de distúrbios metabólicos, especialmente diabetes, ou uma doença ou condição associada com diabetes | |
| ATE506948T1 (de) | Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten | |
| BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
| BR0311548A (pt) | Tiofenos substituìdos, processo para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como medicamento contendo os mesmos | |
| BR0313790A (pt) | Compostos de amida de ácido carboxìlico com efeito antagonista mch, medicamentos contendo estes compostos e processos para sua preparação | |
| BRPI0411906A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos | |
| BR0312851A (pt) | Composto, composição farmacêutica, e, métodos para tratar ou previnir câncer, degeneração macular de tipo úmido ou artrite reumatóide, vascularização anÈmala, nìveis de cobre em excesso em um paciente, obesidade e doença neurodegenerativa em um paciente | |
| BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
| BRPI0514310A (pt) | 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| BRPI0407901A (pt) | derivados de diarilcicloalquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos | |
| BRPI0508177A (pt) | composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação | |
| BR0116653A (pt) | Medicamento contendo uma poliamina como substância ativa | |
| JOP20230173A1 (ar) | أشطر إطالة العمر-النصفي وطرق استخدامها |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |